ASCO 2023 | Highlights in kidney and bladder cancer at ASCO 2023

Benjamin Garmezy, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the Kidney and Bladder Poster Session at ASCO 2023, focusing on three abstracts exploring how patient experience and information can improve patient care. Two of the abstracts concentrated on upfront treatment for metastatic urothelial carcinoma, specifically bladder cancer or upper tract kidney/ureter disease. The approach involved administering chemotherapy initially and subsequently using checkpoint inhibitors or immunotherapy as maintenance based on the response to chemotherapy. The third abstract examined patients with VHL syndrome, a rare condition that leads to various tumor types. It emphasized the challenges patients face regarding surgery tolerance, morbidity, fatigue, and quality of life impacts. The abstract suggested that systemic therapy, despite associated toxicity, could be considered to delay the need for surgery in these patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.